Belite Bio BLTE 深 沪
等待开盘 10-07 09:30:00 美东时间
155.61
-3.570
-2.24%
华盛通- 最 高198.58
- 今 开158.24
- 成交量 18.81万股
- 最 低 150.16
- 昨 收 159.18
- 总市值 386.96万
- 52周最高 200.00
- 市盈率 静 --
- 换手率 756.52%
- 52周最低 86.57
- 委 比 -50.00%
- 总股本 2.49万
- 历史最高 200.00
- 量 比 1.30
- 振 幅 30.42%
- 历史最低 1.10
- 每 手 1
- 风险率 25.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Is Belite Bio Stock Gaining Monday?
Belite Bio (BLTE) stock jumps 3% on positive Phase 3 DRAGON trial data for its Stargardt disease drug candidate tinlarebant.
07-21 01:35
Belite Bio Q1 EPS $(0.45) Beats $(0.63) Estimate
Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.63) by 28.57 percent. This is unchanged from the same period last year.
05-20 18:09
Earnings Scheduled For March 2, 2026
Companies Reporting Before The Bell • Zymeworks (NASDAQ:ZYME) is expected to re...
03-02 19:11
Exploring Belite Bio's Earnings Expectations
Belite Bio (NASDAQ:BLTE) is set to give its latest quarterly earnings report on...
02-28 00:00
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
2025-11-10 19:12
Earnings Outlook For Belite Bio
Belite Bio (NASDAQ:BLTE) is set to give its latest quarterly earnings report on...
2025-11-07 23:02
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen
BioAtla's Ozuriftamab Vedotin (Oz-V) shows 45% ORR and 100% DCR in HPV+ OPSCC patients with 3 prior therapies. Current treatments have 3.4% ORR. BioAtla plans Phase 3 trial discussions with FDA for 2L+ HPV+ OPSCC.
2025-06-02 12:00
HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $60 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $60 price target.
2024-09-12 18:47
Reported Earlier, Belite Bio Taps Hendrik P. N. Scholl of Institute of Molecular and Clinical Ophthalmology Basel (IOB) as Chief Medical Officer
Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its board of directors has appoin...
2024-09-03 15:20
